102.
    发明专利
    未知

    公开(公告)号:NO20011912L

    公开(公告)日:2001-04-18

    申请号:NO20011912

    申请日:2001-04-18

    Applicant: BASF AG

    Abstract: The invention relates to nucleic acid sequences which code for a polypeptide having nitrilase activity, to nucleic acid constructs comprising the nucleic acid sequences, and to vectors comprising the nucleic acid sequences or the nucleic acid constructs. The invention further relates to amino acid sequences which are encoded by the nucleic acid sequences, and to microorganisms comprising the nucleic acid sequences, the nucleic acid constructs or vectors comprising the nucleic acid sequences or the nucleic acid constructs.The invention additionally relates to a process for preparing chiral carboxylic acids from the racemic nitriles.

    104.
    发明专利
    未知

    公开(公告)号:BR9707280A

    公开(公告)日:1999-07-20

    申请号:BR9707280

    申请日:1997-02-11

    Applicant: BASF AG

    Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

    107.
    发明专利
    未知

    公开(公告)号:NO983677L

    公开(公告)日:1998-08-11

    申请号:NO983677

    申请日:1998-08-11

    Applicant: BASF AG

    Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

    109.
    发明专利
    未知

    公开(公告)号:DK0610246T3

    公开(公告)日:1998-01-12

    申请号:DK92920588

    申请日:1992-09-23

    Applicant: BASF AG

    Abstract: PCT No. PCT/EP92/02198 Sec. 371 Date Mar. 18, 1994 Sec. 102(e) Date Mar. 18, 1994 PCT Filed Sep. 23, 1992 PCT Pub. No. WO93/09231 PCT Pub. Date May 13, 1993A novel thrombin inhibitory protein from ticks with a molecular weight of about 26000 dalton and the partial amino acid sequences Val-Ala-Lys-Phe-Ala-X-Asn-Ser-Gly-Ser-Glu-Thr-Gly (SEQ ID NO: 8), His-Ala-Y-Phe-Glu (SEQ ID NO: 3), Arg-Val-Ser-Asp-Phe-Glu (SEQ ID NO: 4), Phe-Val-Tyr-Thr-Ile-Glu (SEQ ID NO: 6), where X and Y can be identical or different and each is a naturally occurring amino acid, is suitable for controlling diseases.

Patent Agency Ranking